Corvus Pharmaceuticals, Inc.’s CRVS share price has surged by 10.33%, which has investors questioning if this is right time ...

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek ...

Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...

We’re thrilled to welcome Richard to our board,” said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. “Richard has a proven track record in the biotechnology sector ...

Corvus Pharmaceuticals highlighted significant progress for soquelitinib, including ongoing Phase 3 trials for T-cell lymphoma and advancements in atopic dermatitis studies. The company has ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from ...

Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have ...

View the CRVS option chain and compare options of Corvus Pharmaceuticals Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to ...

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, ...